Fisetin clears p21+ senescent cells in adipose tissue in this Mayo Clinic pilot — but the effect size is smaller than dasatinib+quercetin, and the human translation of animal data remains unconfirmed.
What Senolytics Do
Senescent cells accumulate with age and secrete the SASP (senescence-associated secretory phenotype), a cocktail of inflammatory cytokines that drives tissue dysfunction. Senolytics selectively clear these cells.
Fisetin vs. D+Q
In the Mayo pilot (n=30, adipose tissue biopsy), fisetin reduced p21+ senescent cells by 25% vs. 42% for dasatinib+quercetin in prior work. Both are statistically significant vs. control, but the magnitude difference matters for protocol selection.
OBS Label Applied
This remains a small pilot with no long-term follow-up. We apply OBS rather than RCT. The mechanism is solid; the clinical translation in humans requires larger, longer studies before dosing protocols can be recommended.
